Advances in the management of heart failure: the role of ivabradine

References

• BraunwaldEHeart FailureJACC Heart Fail20131112024621794
   PubMed Web of Science ®Google Scholar
• LaribiSAoubaANikolaouMTrends in death attributed to heart failure over the past two decades in EuropeEur J Heart Fail201214323423922237388
   PubMed Web of Science ®Google Scholar
• PonikowskiPVoorsAAAnkerSD2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESCEur Heart J201637272129220027206819
   PubMed Web of Science ®Google Scholar
• TannenbaumSSayerGTAdvances in the pathophysiology and treatment of heart failure with preserved ejection fractionCurr Opin Cardiol201530325025825807227
   PubMed Web of Science ®Google Scholar
• YancyCWJesupMBozkurtB2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesCirculation2013128161810185223741057
   PubMed Web of Science ®Google Scholar
• LevineHJRest heart rate and life expectancyJ Am Coll Cardiol1997304110411069316546
   PubMed Web of Science ®Google Scholar
• FoxKBorerJSCammAJHeart Rate Working GroupResting heart rate in cardiovascular diseaseJ Am Coll Cardiol200750982383017719466
   PubMed Web of Science ®Google Scholar
• HeuschGHeart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agentsBr J Pharmacol200815381589160118223669
   PubMed Web of Science ®Google Scholar
• ColinPGhalehBMonnetXHittingerLBerdeauxAEffect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogsJ Pharmacol Exp Ther2004308123624014569053
   PubMed Web of Science ®Google Scholar
• CustodisFBaumhäkelMSchlimmerNHeart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient miceCirculation2008117182377238718443241
   PubMed Web of Science ®Google Scholar
• DrouinAGendronMEThorinEGillisMAMahlberg-GaudinFTardifJCChronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic miceBr J Pharmacol2008154474975718414390
   PubMed Web of Science ®Google Scholar
• JohansenCDOlsenRHPedersenLRResting, night-time, and 24 h heart rate as markers of cardiovascular risk in middle-aged and elderly men and women with no apparent heart diseaseEur Heart J201334231732173923306958
   PubMed Web of Science ®Google Scholar
• MulderPBarbierSChagraouiALong-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failureCirculation2004109131674167914981003
   PubMedGoogle Scholar
• ReilJCTardifJCFordISelective heart rate reduction with ivabradine unloads the left ventricle in heart failure patientsJ Am Coll Cardiol201362211977198523933545
   PubMed Web of Science ®Google Scholar
• ReilJCHohlMReilGHHeart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fractionEur Heart J201334362839284922833515
   PubMedGoogle Scholar
• SwedbergKKomajdaMBöhmMSHIFT InvestigatorsIvabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled studyLancet2010376974487588520801500
   PubMed Web of Science ®Google Scholar
• TardifJCO’MearaEKomajdaMSHIFT InvestigatorsEffects of selective heart rate reduction with ivabradine on left ventricular remodeling and function: results from the SHIFT echocardiography substudyEur Heart J201132202507251521875858
   PubMed Web of Science ®Google Scholar
• BeerePAGlagovSZarinsCKRetarding effect of lowered heart rate on coronary atherosclerosisScience198422646711801826484569
   PubMed Web of Science ®Google Scholar
• FoxKFordIStegPGTardifJCTenderaMFerrariRSIGNIFY InvestigatorsIvabradine in stable coronary artery disease without clinical heart failureN Engl J Med2014371121091109925176136
   PubMed Web of Science ®Google Scholar
• GentSKleinbongardPDammanPNeuhäuserMHeuschGHeart rate reduction and longevity in miceBasic Res Cardiol20151102225589054
   PubMed Web of Science ®Google Scholar
• HeuschGPleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reductionBr J Pharmacol2008155797097118846042
   PubMed Web of Science ®Google Scholar
• HeuschGSkyschallyAGresPvan CasterPSchilawaDSchulzRImprovement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reductionEur Heart J200829182265227518621770
   PubMed Web of Science ®Google Scholar
• KleinbongardPGedikNWittingPFreedmanBKlöckerNHeuschGPleiotropic, heart rate-independent cardioprotection by ivabradineBr J Pharmacol2015172174380439026076181
   PubMed Web of Science ®Google Scholar
• RienzoMMelkaJBizeAIvabradine improves left ventricular function during chronic hypertension in conscious pigsHypertension201565112212925350985
   PubMed Web of Science ®Google Scholar
• SkalidisEHamilosMIChlouverakisGZacharisEAVardasPEIvabradine improves coronary flow reserve in patients with stable coronary artery diseaseAtherosclerosis2011215116016521183181
   PubMed Web of Science ®Google Scholar
• BöhmMSwedbergKKomajdaMSHIFT InvestigatorsHeart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trialLancet2010376974488689420801495
   PubMed Web of Science ®Google Scholar
• BöhmMBorerJFordIHeart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT studyClin Res Cardiol20131021112222575988
   PubMed Web of Science ®Google Scholar
• CastagnoDSkaliHTakeuchiMCHARM InvestigatorsAssociation of heart rate and outcome in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) programJ Am Coll Cardiol201259201785179522575317
   PubMedGoogle Scholar
• FoxKFordIStegGTenderaMRobertsonMFerrariRBEAUTIFUL InvestigatorsHeart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trialLancet2008372964181782118757091
   PubMed Web of Science ®Google Scholar
• FrankeJWolterJSMemeLOptimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?Clin Res Cardiol20131021233122760479
   PubMed Web of Science ®Google Scholar
• LogeartDSerondeMFDegrootePRaised heart rate at discharge after acute heart failure is an independent predictor of one-year mortalityEur Heart J201232Suppl 1485
   Google Scholar
• BöhmMPerezA-CJhundPSI-Preserve Committee and InvestigatorsRelationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)Eur J Heart Fail201416777878724864045
   PubMed Web of Science ®Google Scholar
• MaederMTKayeDMDifferential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fractionInt J Cardiol2012155224925621035207
   PubMed Web of Science ®Google Scholar
• TakadaTSakataYMiyataSCHART-2 InvestigatorsImpact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 StudyEur J Heart Fail201416330931624464774
   PubMed Web of Science ®Google Scholar
• HowlettJGDoes slow and steady win the race?J Am Coll Cardiol201259201796179822575318
   PubMed Web of Science ®Google Scholar
• Zorn-PaulyKPelzmannBLangPEndotoxin impairs the human pacemaker current IFShock200728665566118092381
   PubMedGoogle Scholar
• LiNCsepeTAHansenBJMolecular mapping of sinoatrial node HCN channel expression in the human heartCirc Arrhythm Electrophysiol2015851219122726304511
   PubMed Web of Science ®Google Scholar
• DiFrancescoDThe role of the funny current in pacemaker activityCirc Res2010106343444620167941
   PubMed Web of Science ®Google Scholar
• HeuschGBaumgartDCamiciPalpha-Adrenergic coronary vasoconstriction and myocardial ischemia in humansCirculation2000101668969410673263
   PubMed Web of Science ®Google Scholar
• MesircaPTorrenteAGMangoniMEFunctional role of voltage gated Ca(2+) channels in heart automaticityFront Physiol201561925698974
   PubMed Web of Science ®Google Scholar
• WildersRComputer modelling of the sinoatrial nodeMed Biol Eng Comput200745218920717115219
   PubMed Web of Science ®Google Scholar
• BogdanovKYVinogradovaTMLakattaEGSinoatrial nodal cell ryanodine receptor and Na(+)-Ca(2+) exchanger: molecular partners in pacemaker regulationCirc Res200188121254125811420301
   PubMed Web of Science ®Google Scholar
• LakattaEGDiFrancescoDWhat keeps us ticking: a funny current, a calcium clock, or both?J Mol Cell Cardiol200947215717019361514
   PubMed Web of Science ®Google Scholar
• YanivYLakattaEGMaltsevVAFrom two competing oscillators to one coupled-clock pacemaker cell systemFront Physiol201562825741284
   PubMed Web of Science ®Google Scholar
• YanivYSirenkoSZimanBDSpurgeonHAMaltsevVALakattaEGNew evidence for coupled clock regulation of the normal automaticity of sinoatrial nodal pacemaker cells: bradycardic effects of ivabradine are linked to suppression of intracellular Ca(2)(+) cyclingJ Mol Cell Cardiol201362808923651631
   PubMed Web of Science ®Google Scholar
• YanivYLyashkovAESirenkoSStochasticity intrinsic to coupled-clock mechanisms underlies beat-to-beat variability of spontaneous action potential firing in sinoatrial node pacemaker cellsJ Mol Cell Cardiol20147711025257916
   PubMed Web of Science ®Google Scholar
• TsujiHLarsonMGVendittiFJJrImpact of reduced heart rate variability on risk for cardiac events. The Framingham Heart StudyCirculation19969411285028558941112
   PubMed Web of Science ®Google Scholar
• PonikowskiPAnkerSDChuaTPDepressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathyAm J Cardiol19977912164516509202356
   PubMed Web of Science ®Google Scholar
• KazmiSZZhangZHAzizWInverse correlation between heart rate variability and heart rate demonstrated by linear and nonlinear analysisPLoS One2016116e015755727336907
   PubMed Web of Science ®Google Scholar
• ManginLSwynghedauwBBenisAThibaultNLereboursGCarréFRelationships between heart rate and heart rate variability: study in conscious ratsJ Cardiovasc Pharmacol19983246016079781928
   PubMed Web of Science ®Google Scholar
• Dias da SilvaVJTobaldiniERocchettiMModulation of sympathetic activity and heart rate variability by ivabradineCardiovasc Res20151081313826101263
   PubMed Web of Science ®Google Scholar
• BöhmMBorerJSCammJTwenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudyEur J Heart Fail201517551852625801408
   PubMed Web of Science ®Google Scholar
• KurtogluEBaltaSKarakusYIvabradine improves heart rate variability in patients with nonischemic dilated cardiomyopathyArq Bras Cardiol2014103430831425119894
   PubMed Web of Science ®Google Scholar
• EvansNDGodfreyKRChapmanMJChappellMJAaronsLDuffullSBAn identifiability analysis of a parent-metabolite pharmakokinetic model for ivabradineJ Pharmacokinet Pharmacodyn20012819310511253617
   PubMed Web of Science ®Google Scholar
• Francois-BouchardMSimoninGBossantMJBoursier-NeyretCSimultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometryJ Chromatogr B Biomed Sci Appl2000745226126911043745
   PubMed Web of Science ®Google Scholar
• RagueneauILaveilleCJochemsenRResplandyGFunck-BrentanoCJaillonPPharmakokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteersClin Pharmacol Ther19986421922039728900
   PubMed Web of Science ®Google Scholar
• De FerrariGMMazzueroAAgnesinaLFavourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failureEur J Heart Fail200810655055518486549
   PubMed Web of Science ®Google Scholar
• StegPLopez-de-SàESchieleFVIVIFY (eValuation of the Intra-Venous If inhibitor ivabradine after ST segment elevation mYocardial infarction) InvestigatorsSafety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot studyEur Heart J Acute Cardiovasc Care20132327027924222839
   PubMedGoogle Scholar
• ProndzinskyRLemmHSwyterMIntra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndromeCrit Care Med201038115216019770739
   PubMed Web of Science ®Google Scholar
• KlöcknerURueckschlossUGrossmannCDifferential reduction of HCN channel activity by various types of lipopolysaccharideJ Mol Cell Cardiol201151222623521609720
   PubMed Web of Science ®Google Scholar
• KlöcknerURueckschlossUGrossmannCInhibition of cardiac pacemaker channel hHCN2 depends on intercalation of lipopolysaccharide into channel-containing membrane microdomainsJ Physiol201459261199121124366264
   PubMed Web of Science ®Google Scholar
• BarbutiADiFrancescoDThe “fun” side of sepsisJ Physiol20145926117124634015
   PubMed Web of Science ®Google Scholar
• EbeltHGeißlerIRucciusSDirect inhibition, but indirect sensitization of pacemaker activity to sympathetic tone by the interaction of endotoxin with HCN-channelsClin Exp Pharmacol Physiol201542887488025933122
   PubMed Web of Science ®Google Scholar
• ScheruebelSKoyaniCNHallströmSIf blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytesJ Mol Cell Cardiol201472647324583250
   PubMedGoogle Scholar
• BonadeiIVizzardiESciattiEIs there a role for ivabradine beyond its conventional use?Cardiovasc Ther201432418919224828443
   PubMed Web of Science ®Google Scholar
• AnterEJessupMCallansDJAtrial fibrillation and heart failure: treatment considerations for a dual epidemicCirculation2009119182516252519433768
   PubMed Web of Science ®Google Scholar
• MaiselWHStevensonLWAtrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapyAm J Cardiol2003916A2D8D
   PubMed Web of Science ®Google Scholar
• FoxKFordIStegGTenderaMFerrariRBEAUTIFUL InvestigatorsIvabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trialLancet2008372964180781618757088
   PubMed Web of Science ®Google Scholar
• ZugckCMartinkaPStöcklGIvabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practiceAdv Ther201431996197425160945
   PubMed Web of Science ®Google Scholar
• WerdanKEbeltHNudingSHöpfnerFHackGMüller-WerdanUIvabradine in combination with betablocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS studyClin Res Cardiol2012101536537322231643
   PubMed Web of Science ®Google Scholar
• ChanMMLamCSHow do patients with heart failure with preserved ejection fraction die?Eur J Heart Fail201315660461323610137
   PubMed Web of Science ®Google Scholar
• ZakeriRBorlaugBAMcNultySEImpact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary studyCirc Heart Fail20147112313024162898
   PubMed Web of Science ®Google Scholar
• BavishiCChatterjeeSAtherSPatelDMesserliFHBeta-blockers in heart failure with preserved ejection fraction: a meta-analysisHeart Fail Rev201520219320125034701
   PubMed Web of Science ®Google Scholar
• ConraadsVMMetraMKampOEffects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD studyEur J Heart Fail201214221922522147202
   PubMed Web of Science ®Google Scholar
• EdelmannFMusial-BrightLGelbrichGCIBIS-ELD Investigators and Project Multicenter Trials in the Competence Network Heart FailureTolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: insights from the CIBIS-ELD trialJACC Heart Fail20164214014926682793
   PubMed Web of Science ®Google Scholar
• LiuFChenYFengXTengZYuanYBinJEffects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysisPLoS One201493e9055524599093
   PubMed Web of Science ®Google Scholar
• LundLHBensonLDahlströmUEdnerMFribergLAssociation between use of β-blockers and outcomes in patients with heart failure and preserved ejection fractionJAMA2014312192008201825399276
   PubMed Web of Science ®Google Scholar
• EdelmannFWachterRSchmidtAGAldo-DHF InvestigatorsEffect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trialJAMA2013309878179123443441
   PubMed Web of Science ®Google Scholar
• PittBPfefferMAAssmannSFTOPCAT InvestigatorsSpironolactone for heart failure with preserved ejection fractionN Engl J Med2014370151383139224716680
   PubMed Web of Science ®Google Scholar
• PfefferMAClaggettBAssmanSFRegional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trialCirculation20151311344225406305
   PubMed Web of Science ®Google Scholar
• GuJFanYQBianLLong-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: a retrospective observational studyEur J Prev Cardiol201623131421142826915580
   PubMed Web of Science ®Google Scholar
• KosmalaWHollandDJRojektAWrightLPrzewlocka-KosmalaMMarwickTHEffect of If channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trialJ Am Coll Cardiol201362151330133823916925
   PubMed Web of Science ®Google Scholar
• SimantirakisENNakouESKallergisEMLong-term effect of If-channel inhibition on diastolic function and exercise capacity in heart failure patients with preserved ejection fractionInt J Cardiol201518791125828300
   PubMed Web of Science ®Google Scholar
• Fischer-RasokatUHonoldJLochmannDβ-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling indexClin Res Cardiol2016105652753426687495
   PubMed Web of Science ®Google Scholar
• AdamyanKGTumasyanLRChilingaryanALTunyanLGEfficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic functionEur Heart J201536Suppl 1666667
   Google Scholar
• De MasiDeLucaGIvabradine and diastolic heart failureJ Am Coll Cardiol20125913 Suppl 1E1009
   Google Scholar
• PalNSivaswamyNMahmoudMEffect of selective heart rate slowing in heart failure with preserved ejection fractionCirculation2015132181719172526338956
   PubMed Web of Science ®Google Scholar
• KitzmanDWConventional wisdom in heart failure treatment challenged again: does heart rate lowering worsen exercise intolerance in heart failure with preserved ejection fraction?Circulation2015132181687168926338957
   PubMed Web of Science ®Google Scholar
• ShahSJMatchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matterJ Am Coll Cardiol201362151339134223916923
   PubMed Web of Science ®Google Scholar
• LogeartDIsnardRResche-RigonMHeart Failure of the French Society of CardiologyCurrent aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA studyEur J Heart Fail201315446547623186936
   PubMed Web of Science ®Google Scholar
• MebazaaAParissisJPorcherRShort-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methodsIntensive Care Med201137229030121086112
   PubMed Web of Science ®Google Scholar
• SenniMGavazziAOlivaFIN HF Outcome InvestigatorsIn-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome RegistryInt J Cardiol2014173216316924630337
   PubMed Web of Science ®Google Scholar
• AroutunovAGAroutunovGPVolkovaALBylovaNAPrognosis of heart rate control on decompensated heart failure patientsHeart Lung Circ2008171S5S6
   PubMedGoogle Scholar
• SargentoLSatendraMLongoSLousadaNdos ReisRPHeart rate reduction with ivabradine in patients with acute decompensated systolic heart failureAm J Cardiovasc Drugs201414322923524452599
   PubMed Web of Science ®Google Scholar
• CavusogluYMertUNadirAMutluFMorradBUlusTIvabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failureJ Cardiovasc Med (Hagerstown)201516960360924922198
   PubMed Web of Science ®Google Scholar
• LinkAReilJCSelejanSBöhmMEffect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failureClin Res Cardiol200998851351519547907
   PubMed Web of Science ®Google Scholar
• DoeschAOCelikSEhlermannPHeart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradineTransplantation200784898899617989604
   PubMed Web of Science ®Google Scholar
• DoeschAOAmmonKKonstandinMHeart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipientsTransplantation200988683584119920784
   PubMed Web of Science ®Google Scholar
• SekarBCritchleyWRWilliamsSGShawSMShould we consider heart rate reduction in cardiac transplant recipients?Clin Cardiol2013362687322911227
   PubMed Web of Science ®Google Scholar
• ZwickerCBeckerMLepperWKochKCWestenfeldRCardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradineCardiology2010116317417720628253
   PubMed Web of Science ®Google Scholar
• LibhaberESliwaKBachelierKLamontKBöhmMLow systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathyInt J Cardiol201519037638225966297
   PubMed Web of Science ®Google Scholar
• Hilfiker-KleinerDHaghikiaANonhoffJBauersachsJPeripartum cardiomyopathy: current management and future perspectivesEur Heart J201536181090109725636745
   PubMed Web of Science ®Google Scholar
• HaghikiaATongersJBerlinerDEarly ivabradine treatment in patients with acute peripartum cardiomyopathy: subanalysis of the German PPCM registryInt J Cardiol201621616516727156059
   PubMed Web of Science ®Google Scholar
• BonadeiISciattiEVizzardiED’AloiaAMetraMIvabradine during cardiogenic shock: a clinical case and review of the literatureHeart Lung2015441575825240447
   PubMed Web of Science ®Google Scholar
• BarillàFPannaraleGTorromeoCIvabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective studyClin Drug Investig20163610849856
   PubMed Web of Science ®Google Scholar
• WerdanKNudingSMüller-WerdanUPotential Pathophysiological Mechanisms in Septic Cardiomyopathy: An Overview Frontiers in Myocardia1PapaioannouVasilios ESharjah, UAEBentham Science Publishers Ltd2015340
   Google Scholar
• SanderOWeltersIDFoexPSearJWImpact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complicationsCrit Care Med2005331818815644652
   PubMed Web of Science ®Google Scholar
• HokeRSMüller-WerdanULautenschägerCWerdanKEbeltHHeart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational studyClin Res Cardiol2012101213914722048696
   PubMed Web of Science ®Google Scholar
• MorelliAErtmerCWestphalMEffect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trialJAMA2013310161683169124108526
   PubMed Web of Science ®Google Scholar
• NudingSEbeltEHokeRSReducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I(f) (funny channel current) inhibitor ivabradine MODI(f)Y TrialClin Res Cardiol20111001091592321638157
   PubMed Web of Science ®Google Scholar
• ThomsenJHNielsenNHassagerCBradycardia during targeted temperature management: an early marker of lower mortality and favorable neurologic outcome in comatose out-of-hospital cardiac arrest patientsCrit Care Med2016442308318
   PubMed Web of Science ®Google Scholar
• SwedbergKKomajdaMBöhmMSHIFT InvestigatorsEffects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) studyJ Am Coll Cardiol201259221938194522617188
   PubMedGoogle Scholar
• BocchiEABöhmMBorerJSSHIFT investigatorsEffect of combining ivabradine and β-blockers: focus on the use of carvedilol in the SHIFT populationCardiology2015131421822425968495
   PubMed Web of Science ®Google Scholar
• VolterraniMCiceGCaminitGEffect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial)Int J Cardiol2011151221822421764469
   PubMed Web of Science ®Google Scholar
• SimonLGhalehBPuybassetLGiudicelliJFBerdeauxACoronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogsJ Pharmacol Exp Ther199527526596667473152
   PubMed Web of Science ®Google Scholar
• EkmanIChassanyOKomajdaMHeart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure results from the SHIFT studyEur Heart J201132192395240421875859
   PubMed Web of Science ®Google Scholar
• Lesman-LeegteIJaarsmaTCoyneJCHillegeHLvan VeldhuisenDJSandermanRQuality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age- and gender-matched community controlsJ Card Fail2009151172319181289
   PubMed Web of Science ®Google Scholar
• JuengerJSchellbergDKraemerSHealth related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variablesHeart200287323524111847161
   PubMed Web of Science ®Google Scholar
• RiccioniGMascioccoLBenvenutoAIvabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA studyPharmacology2013925–627628024296869
   PubMed Web of Science ®Google Scholar
• DobreDde JongsteMJLHaaijer-RuskampFMSandermannRvan VeldhuisenDJRanchorAVThe enigma of quality of life in patients with heart failureInt J Cardiol2008125340740917400313
   PubMed Web of Science ®Google Scholar
• DobreDvan JaarsfeldCHMdeJongsteMJLRuskampFMHRanchorAVThe effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysisPharmacoepidemiol Drug Saf200716215215916555368
   PubMed Web of Science ®Google Scholar
• UdelsonJEFeldmanAMGreenbergBRandomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonisms with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunctionCirc Heart Fail20103334735320299607
   PubMed Web of Science ®Google Scholar
• TavazziLSwedbergKKomajdaMSHIFT InvestigatorsEfficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT studyEur J Heart Fail201315111296130323803951
   PubMed Web of Science ®Google Scholar
• StewartSRiegelBBoydCEstablishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): a multidisciplinary position statementInt J Cardiol201621211027015641
   PubMed Web of Science ®Google Scholar